Markets

Obsidian Therapeutics To Present Updated Data In Patients With Immune-Checkpoint Inhibitor-Resistant Advanced Melanoma From Its Phase 1 Study And The Phase 1/2 Agni-01 Multicenter Study Of Amsokigene Autoleucel

Oct 2, 2026 · 09:09 AM ET· updated 1h ago

Presentations at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place in Phoenix, AZ, November 4-8, 2026. The poster presentation will summarize pooled safety data across the FIH study and

Why It Matters

Obsidian Therapeutics will show new test results for a cancer medicine. Doctors will review the safety data to see if the treatment works well.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

OBX13.47

+0.14 (+1.09%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.